BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35587164)

  • 1. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Kong SY; Song JJ; Jin YQ; Deng MJ; Yan JX
    Acta Clin Belg; 2023 Apr; 78(2):171-179. PubMed ID: 35587164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
    Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
    Front Immunol; 2022; 13():913464. PubMed ID: 35677059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Hepatic Arterial Infusion Chemotherapy and Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Liu H; Qin X; Jiang H; Sun C; Wu M; Xu Z; Lu T; Ma X; Han Z
    J Gastrointestin Liver Dis; 2022 Sep; 31(3):336-343. PubMed ID: 36112704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
    Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
    Liu J; Zhang J; Wang Y; Shu G; Lou C; Du Z
    Medicine (Baltimore); 2022 Dec; 101(51):e32390. PubMed ID: 36595819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
    Li QJ; He MK; Chen HW; Fang WQ; Zhou YM; Xu L; Wei W; Zhang YJ; Guo Y; Guo RP; Chen MS; Shi M
    J Clin Oncol; 2022 Jan; 40(2):150-160. PubMed ID: 34648352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
    Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis.
    Ji J; Zhang Z; Hou Z; Qiu G; Mi S; Jin Z; Huang J
    Clin Res Hepatol Gastroenterol; 2024 Apr; 48(4):102313. PubMed ID: 38453011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma: A meta-analysis.
    Long GB; Xiao CW; Zhao XY; Zhang J; Li X
    Medicine (Baltimore); 2020 Jun; 99(26):e20745. PubMed ID: 32590750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis.
    Si T; Huang Z; Khorsandi SE; Ma Y; Heaton N
    Front Bioeng Biotechnol; 2022; 10():1010824. PubMed ID: 36237208
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk.
    Wu Z; Gao J; Zhuang W; Yang J; Guo W
    J Cancer Res Ther; 2022 Apr; 18(2):345-351. PubMed ID: 35645099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of transarterial chemoembolization combined with targeted therapy and immunotherapy versus with targeted monotherapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
    Feng J; Zhao Y; Zhai L; Zhou J
    Medicine (Baltimore); 2024 May; 103(18):e38037. PubMed ID: 38701263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma.
    Guo JH; Liu SX; Gao S; Kou FX; Zhang X; Wu D; Li XT; Chen H; Wang XD; Liu P; Zhang PJ; Xu HF; Cao G; Zhu LZ; Yang RJ; Zhu X
    World J Gastroenterol; 2020 Jul; 26(27):3975-3988. PubMed ID: 32774071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Kong S; Yu H; Wang H; Song J; Yan J
    Clin J Gastroenterol; 2023 Dec; 16(6):793-802. PubMed ID: 37740882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
    Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
    Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
    Duan R; Gong F; Wang Y; Huang C; Wu J; Hu L; Liu M; Qiu S; Lu L; Lin Y
    World J Surg Oncol; 2023 Mar; 21(1):120. PubMed ID: 37004052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma.
    Chen B; Dai H; Yang J; Zhang G; Wen C; Xiang X; Lin R; Huang Y
    Curr Cancer Drug Targets; 2023; 23(7):564-571. PubMed ID: 36790005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
    J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization.
    Hsu SJ; Xu X; Chen MP; Zhao ZY; Wang Y; Yin X; Zhang L; Ge NL; Chen Y; Wang YH; Luo JF; Ren ZG; Chen RX
    Acad Radiol; 2021 Nov; 28 Suppl 1():S157-S166. PubMed ID: 33653656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
    Zhang X; Wang K; Wang M; Yang G; Ye X; Wu M; Cheng S
    Oncotarget; 2017 Apr; 8(17):29416-29427. PubMed ID: 28177886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.